Roundtable: Discussing the Regulatory Requirements for the Best Practices for In Vivo Delivery of CRISPR/Cas9 Technology

Time: 9:30 am
day: Conference Day Two


  • Leveraging guidance from gene therapy to CRISPR/Cas9 gene editing
  • Capturing the evolution of regulatory guidance in gene editing
  • Exploring the FDA’s perspective on the in vivo pipeline for delivery